Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children

Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study

“…No new safety concerns were identified with JE-CV in our study. The safety results support those from other JE-CV studies, which have also demonstrated a good safety profile when administered as a single dose to toddlers and children in other endemic Asian countries (Chokephaibulkit et al, 2010;Feroldi et al, 2014;Kim et al, 2014) and adults in non-endemic countries (Nasveld et al, 2010;Torresi et al, 2010), and as a booster dose in children following primary vaccination with JE-CV or other JE vaccines (Chokephaibulkit et al, 2010(Chokephaibulkit et al, , 2016Chotpitayasunondh et al, 2017;Kosalaraksa et al, 2016;Feroldi et al, 2013;Janewongwirot et al, 2016). In this study AEs most frequently occurred in the youngest age group, 9 months to 2 years, when compared to the older age groups.…”

Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV–Primed Children in the Philippines

“…The immune response elicited by the JE-CV booster does not appear to be dependent on the JE vaccine administered during primary vaccination, nor on the interval between primary and booster. The magnitude of response after JE-CV booster in our study was similar to JE-CV booster responses observed in other studies following primary vaccination with JE-CV or other JE vaccines, even when the booster was administered up to 5 years later [ 12 , 13 ]. Thus, a long-lasting JE-CV booster antibody response would be expected irrespective of the previous JE vaccine.…”

Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease

“…120 In Thai and Philippine children aged 12-24 months, the vaccine could produce 96% SPR after a single dose, 22123 and boost NAb responses elicited earlier by MBDI vaccine with SCR of >90% and SPR of 100% in 2-5-year-old children, 31 as well as 2 years following priming with JE-CV. 124 In a head-to-head comparison of JE-CV and SA14-14-2 LAV vaccines in 12-18-monthold Thai and 12-24-month-old South Korean children, SPRs were equivalent to each other, whereas 28-day GMTs were higher, albeit not statistically significant, with JE-CV than with SA14-14-2 LAV vaccine., 125,126 JE-CV has also been shown to elicit anamnestic responses and significantly increase GMTs in 1-to-5-year-old Thai children who had been vaccinated 9-13 or 12-24 months earlier with the SA-14-14-2 LAV vaccine; 127,128 incidentally, the responses were slightly, but not significantly higher when the booster with JE-CV was later than earlier.…”